CN107998151A - Compound kangfuxin liquid liniment and preparation method thereof - Google Patents
Compound kangfuxin liquid liniment and preparation method thereof Download PDFInfo
- Publication number
- CN107998151A CN107998151A CN201810007411.1A CN201810007411A CN107998151A CN 107998151 A CN107998151 A CN 107998151A CN 201810007411 A CN201810007411 A CN 201810007411A CN 107998151 A CN107998151 A CN 107998151A
- Authority
- CN
- China
- Prior art keywords
- salicylic acid
- kangfuxin liquid
- compound
- tincture
- kangfuxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 77
- 150000001875 compounds Chemical class 0.000 title claims abstract description 46
- 229940040145 liniment Drugs 0.000 title claims abstract description 45
- 239000000865 liniment Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims description 12
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 108
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 54
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 54
- 229940098465 tincture Drugs 0.000 claims abstract description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 240000000203 Salix gracilistyla Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 26
- 201000010099 disease Diseases 0.000 abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 21
- 208000005373 Dyshidrotic Eczema Diseases 0.000 abstract description 20
- 201000011414 pompholyx Diseases 0.000 abstract description 20
- 208000017520 skin disease Diseases 0.000 abstract description 13
- 208000002474 Tinea Diseases 0.000 abstract description 11
- 241000130764 Tinea Species 0.000 abstract description 11
- 206010046750 Urticaria papular Diseases 0.000 abstract description 11
- 241001480043 Arthrodermataceae Species 0.000 abstract description 10
- 230000037304 dermatophytes Effects 0.000 abstract description 10
- 208000008664 papular urticaria Diseases 0.000 abstract description 10
- 208000007712 Tinea Versicolor Diseases 0.000 abstract description 6
- 206010056131 Tinea versicolour Diseases 0.000 abstract description 6
- 230000001329 hyperkeratotic effect Effects 0.000 abstract description 6
- 201000010618 Tinea cruris Diseases 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000002651 drug therapy Methods 0.000 abstract description 2
- 206010040882 skin lesion Diseases 0.000 description 22
- 231100000444 skin lesion Toxicity 0.000 description 22
- 208000003251 Pruritus Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000003870 salicylic acids Chemical class 0.000 description 5
- 230000001139 anti-pruritic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 206010041955 Stasis dermatitis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- -1 anti-inflammatory Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 201000003929 dermatomycosis Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000005299 metal allergy Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000013486 operation strategy Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Insects & Arthropods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of compound Kangfuxin Liquid liniment, include the raw material of volumes below ratio：49 51ml of salicylic acid tincture, 73 77ml of Kangfuxin Liquid, wherein salicylic acid tincture add the ethanol of concentration of volume percent 75% to be settled to 100ml and are formulated by 4g salicylic acid tinctures.The invention, which overcomes, is used alone the shortcomings that Kangfuxin Liquid, salicylic acid tincture or other some skin diseases of drug therapy (such as pompholyx, dermatophyte class disease (such as jock itch, blister squama type and hyperkeratotic pattern tinea of feet and hands, tinea versicolor), papular urticaria etc.) do not reach good therapeutic effect in the treatments of existing cutaneous diseases, have the advantages that can it is good to the treating skin disease such as such as pompholyx effect, patient satisfaction is high.
Description
Technical field
The present invention relates to a kind of compound Kangfuxin Liquid liniment and preparation method thereof, applies the treatment neck in cutaneous diseases
Domain.
Background technology
Kangfuxin Liquid and salicylic acid tincture are the common medicaments of existing treatment skin disease institute.Wherein, Kangfuxin Liquid is light brown
The liquid of color, gas are micro- stench, sweet.Its is promoting blood circulation, nourishing yin and promoting granulation；It is for oral administration to can be used for stagnation of blood stasis, bleeding of having a stomachache, stomach, ten
Two Duodenalulcers and deficiency of Yin tuberculosis, phthisical auxiliary treatment；External application can be used for metal-inflicted wound, wound, ulcer, fistula, burn,
Scald, the treatment of bedsore wound.Salicylic acid tincture is the one kind being made into by the ethanol that salicylic acid and concentration of volume percent are 75%
Solution, has the function of sterilizing and itch-relieving.
However, in the therapy field of cutaneous diseases, for single in the treatment of some skin diseases (such as pompholyx etc.)
Solely good therapeutic effect is not reached using Kangfuxin Liquid, salicylic acid tincture or other medicines.
Therefore provide it is a kind of can compound rehabilitation good to the treating skin disease such as such as pompholyx effect, that patient satisfaction is high it is new
Liquid liniment and preparation method thereof oneself become when business urgently.
The content of the invention
In order to overcome exclusive use Kangfuxin Liquid in the treatment of existing cutaneous diseases, salicylic acid tincture or other medicines to control
Treat some skin diseases (such as pompholyx, dermatophyte class disease (such as jock itch, blister squama type and hyperkeratotic pattern tinea of feet and hands, flower
Spot tinea etc.), papular urticaria etc.) the shortcomings that not reaching good therapeutic effect, it is new that the present invention provides a kind of compound rehabilitation
Liquid liniment and preparation method thereof, have the advantages that can it is good to the treating skin disease such as such as pompholyx effect, patient satisfaction is high.
Technical scheme is as follows：
A kind of compound Kangfuxin Liquid liniment, includes the raw material of volumes below ratio：
Salicylic acid tincture 49-51ml
Kangfuxin Liquid 73-77ml,
Wherein salicylic acid tincture by 4g salicylic acid tinctures add the ethanol of concentration of volume percent 75% be settled to 100ml prepare and
Into.
Pompholyx is also known as dysidria rash, is one kind of skin eczema, the side for betiding hand or foot of symmetry, is hair
The raw blister dermatoses in palm plantar.Medical is not still fully aware of for the cause of disease of pompholyx, and only a few patients are found
Mycotic infection or metal allergy even emotional stress with body elsewhere is related.May be with stress, acrohyperhidrosis, fungi sense
The factor such as dye and allergy is related, and summer is common.
National Teaching Materials at College level《Skin cypridology》Said in Section seven of the chapter 14 of the 8th edition (people's health is published)
To " pompholyx [prevention and treatment] avoids nervous and mood swing, finds and removes contact stimulus, acrohyperhidrosis
Should proper treatment.Course of disease early stage can apply antihistamine, and partial smearing drug therapy can be outer when the course of disease later stage is using furfur to be main
With 10% urea frost.”.Wherein, because currently without the relatively good medicine for the treatment of pompholyx effect, do not write in teaching material
The bright pompholyx for before the course of disease later stage specifically carries out partial smearing treatment using which kind of medicine.
Fungal dermatopathy, also known as dermatomycosis, refer to as the human skin caused by disease fungus and mucous membrane, hair
One major class infectious diseases of hair and first-class cutaneous appendages.Dermatophyte is the Main Pathogenic Bacteria of fungal dermatopathy, is had strand
Tinea, tinea versicolor, blister squama type and hyperkeratotic pattern tinea of feet and hands etc..The common feature of such disease is：Incidence is high, has
Infectiousness, easily recurrence are infected again.Especially unreasonable, nonstandard treatment can cause recurrent exerbation, treat repeatedly, great shadow
Ring the quality of life of patient.
Papular urticaria is also known as lichen urticatus, strophulus.It is infant and the common allergic skin of children
Disease, but adult can also suffer from this disease.Often several people fall ill at the same time in the same family.Season in spring and autumn occurs more.This disease be one with
Symptom feature and the disease named, actually this disease are insect dermatitis.Clinical characters are being dispersed in property, property is slightly hard, top
There is the papule of phlycten.Periphery has spindle blush, feels itch.
Although the extensive use in treatment of dermatological condition of Kangfuxin Liquid and salicylic acid tincture, salicylic acid tincture is used alone and controls
It is ineffective to treat pompholyx, and Kangfuxin Liquid monotherapy pompholyx is even more invalid.Dermatophyte class is treated using Kangfuxin Liquid
Disease and papular urticaria are invalid, although and treated certain effect with salicylic acid tincture, due to its irritation by force very
More people do not tolerate.The compound Kangfuxin Liquid liniment of the application is innovatively compounded Kangfuxin Liquid, salicylic acid tincture, and preferably
The usage ratio of two raw materials, and compounding is applied to pompholyx, dermatophyte class disease (such as jock itch, blister squama into solution
Bits type and hyperkeratotic pattern tinea of feet and hands, tinea versicolor etc.) and papular urticaria treatment.In the treatment time of 2 years, through upper
The use verification of thousand patients, achieves the effect of being satisfied with.The compound Kangfuxin Liquid liniment has antipruritic, anti-inflammatory, antimycotic, extensive
The function of multiple skin, for patient in medication without significant discomfort, curative compliance is good, curative for effect, satisfaction is high, can be used as and control
Treat pompholyx, dermatophyte class disease, the preferred agents of papular urticaria.
In addition, the compound Kangfuxin Liquid liniment is in the chronic skin lesion applied to varicose eczema, hand drying property skin
There is excellent effect on the treating for skin disease such as scorching, eczema and epifolliculitis.And the clinical practice of its use scope afterwards
It is middle also to have new expansion.
The compound Kangfuxin Liquid liniment, includes the raw material of volumes below ratio：
Salicylic acid tincture 50ml
Kangfuxin Liquid 75ml.
Salicylic content is reasonable in the compound Kangfuxin Liquid liniment of above preferred feedstock ratio, and preferred proportion is used in collocation
The Kangfuxin Liquid of amount, under the cooperation of ethanol, can play good have antimycotic and microorganism, facilitates skin healing, is antipruritic
The side effects such as effect, its stimulation to skin reduce, and effect is good.
A kind of preparation method of above-mentioned compound Kangfuxin Liquid liniment, including following the step of sequentially carrying out：1. take salicylic acid
4g, the ethanol for adding concentration of volume percent 75% thereto are settled to 100ml and mix, and salicylic acid tincture is made；2. needed for taking
The salicylic acid tincture of amount, adds Kangfuxin Liquid, is mixed thereto, that is, the compound Kangfuxin Liquid liniment is made.
Raw material used in the preparation method of the compound Kangfuxin Liquid liniment is simple, is easy to get, and operating procedure is convenient, energy
It is enough to realize batch production and extensive use.Compared with prior art, the present patent application has the following advantages：
1) the compound Kangfuxin Liquid liniment of the application is in pompholyx, the treatment of dermatophyte class disease, papular urticaria
In have the effect of clear and definite, compensate for the deficiency of current pompholyx medicine to a certain extent；
2) the compound Kangfuxin Liquid liniment operation strategies are extensive, it has hand Dry skin pruritus antipruritic and recovery skin
Effect, the therapeutic effect of the chronic skin lesion of varicose eczema, eczema and epifolliculitis might as well.
Embodiment
Raw material information：
Kangfuxin Liquid：Stoste, Inner Mongolia Jingxin Pharmaceutical Co., Ltd..
With reference to specific embodiment, the invention will be further described.
Embodiment 1
A kind of compound Kangfuxin Liquid liniment of the present invention, includes the raw material of volumes below ratio：
Salicylic acid tincture 50ml
Kangfuxin Liquid 75ml,
Wherein salicylic acid tincture by 4g salicylic acid tinctures add the ethanol of concentration of volume percent 75% be settled to 100ml prepare and
Into.
The preparation method of the compound Kangfuxin Liquid liniment, including following the step of sequentially carrying out：1. take salicylic acid 4g, Xiang Qi
The middle ethanol for adding concentration of volume percent 75% is settled to 100ml and mixes, and salicylic acid tincture is made；2. take the desired amount of bigcatkin willow
Sour tincture, adds Kangfuxin Liquid thereto, is mixed, that is, the compound Kangfuxin Liquid liniment is made.
Embodiment 2
A kind of compound Kangfuxin Liquid liniment of the present invention, includes the raw material of volumes below ratio：
Salicylic acid tincture 49ml
Kangfuxin Liquid 77ml,
Wherein salicylic acid tincture by 4g salicylic acid tinctures add the ethanol of concentration of volume percent 75% be settled to 100ml prepare and
Into.
The preparation method of the compound Kangfuxin Liquid liniment, including following the step of sequentially carrying out：1. take salicylic acid 4g, Xiang Qi
The middle ethanol for adding concentration of volume percent 75% is settled to 100ml and mixes, and salicylic acid tincture is made；2. take the desired amount of bigcatkin willow
Sour tincture, adds Kangfuxin Liquid thereto, is mixed, that is, the compound Kangfuxin Liquid liniment is made.
Embodiment 3
A kind of compound Kangfuxin Liquid liniment of the present invention, includes the raw material of volumes below ratio：
Salicylic acid tincture 51ml
Kangfuxin Liquid 73ml,
Wherein salicylic acid tincture by 4g salicylic acid tinctures add the ethanol of concentration of volume percent 75% be settled to 100ml prepare and
Into.
The preparation method of the compound Kangfuxin Liquid liniment, including following the step of sequentially carrying out：1. take salicylic acid 4g, Xiang Qi
The middle ethanol for adding concentration of volume percent 75% is settled to 100ml and mixes, and salicylic acid tincture is made；2. take the desired amount of bigcatkin willow
Sour tincture, adds Kangfuxin Liquid thereto, is mixed, that is, the compound Kangfuxin Liquid liniment is made.Experimental data
(1) pompholyx
Individually using A, B, C, D, (wherein, A (adds concentration of volume percent for salicylic acid tincture A by 1.6g salicylic acids
75% ethanol is settled to 100ml and is formulated), B (adds concentration of volume percent 75% for salicylic acid tincture B by 4g salicylic acids
Ethanol be settled to 100ml and be made mixed liquor, then press 2 with distilled water:3 ratios mix), C is Kangfuxin Liquid, and D is this Shen
Compound Kangfuxin Liquid liniment please) treatment pompholyx, per smearing 1-4 times beyond the highest heavens, (some patientss sometimes apply 1-2 times by other rewetting, often
Secondary 10 minutes, change outer smear after ruptured blister again) it is 1-14 days common, carry out observation of curative effect.
Counted according to following curative effect judging standard：1. recovery from illness：Blister dries up, and skin lesion is disappeared completely, and gargalesthesia disappears, skin
Skin recovers normal；It is 2. effective：Blister is largely dry, and skin lesion is clearly better up to more than 60%, and gargalesthesia substantially mitigates；It is 3. effective：
Blister small part dries up, skin lesion regression 20%-40%, and gargalesthesia mitigates；It is 4. invalid：Skin lesion is disappeared less than 20% or skin lesion is without change
Or continue to aggravate, gargalesthesia with treatment before without mitigate or aggravate on the contrary.
Total effective rate=(recovery from illness number of cases+effective number of cases)/this total cases * 100%.
Statistics is as follows：
In patient 20 using salicylic acid tincture A treatments, there are 12 over the course for the treatment of because stimulation or dry uncomfortable, in
Disconnected treatment；In patient using salicylic acid tincture B treatments, there are 11 over the course for the treatment of because stimulation or dry uncomfortable, interruption is controlled
Treat.Use the ineffective of salicylic acid tincture A, salicylic acid tincture B treatment pompholyx.Treated using C Kangfuxin Liquids completely ineffective.And make
With the patient of D the application compound Kangfuxin Liquid liniment treateds, drug tolerance is good, interrupts and treats without patient, and curative effect is fabulous.
(2) dermatophyte class disease
1) jock itch
Individually using A, B, C, (wherein, A (adds concentration of volume percent for salicylic acid tincture A by 1.6g salicylic acids
75% ethanol is settled to 100ml and is formulated), B is Kangfuxin Liquid, and C is the compound Kangfuxin Liquid liniment of the application) treatment stock
Tinea, per smearing 1-4 times beyond the highest heavens, carries out observation of curative effect in common 2-6 weeks.
Curative effect judging standard：1. recovery from illness：Skin lesion is disappeared completely, and gargalesthesia disappears；It is 2. effective：Skin lesion substantially disappear up to 60% with
On, gargalesthesia substantially mitigates；It is 3. effective：Skin lesion regression 20%-40%, gargalesthesia mitigate；It is 4. invalid：Skin lesion is disappeared less than 20%, or
Skin lesion without change or continue to aggravate, gargalesthesia with treatment before without mitigate or aggravate on the contrary.
Total effective rate=(recovery from illness number of cases+effective number of cases)/this total cases * 100%.
Statistics is as follows：
| N (example) | Fully recover (example) | Effective (example) | Effectively (example) | Invalid (example) | Efficient (%) | |
| A | 20 | 8 (40%) | 5 (25%) | 3 (15%) | 4 (20%) | 80 |
| B | 12 | 0 | 0 | 0 | 12 | 0 |
| C | 50 | 42 (84%) | 5 (10%) | 3(6) | 0 | 100 |
When using salicylic acid tincture A treatments, there are 8 the patient feels discomforts, wherein 4 patient midways abandon treating.Use C
There are few patients to tell slight discomfort during the compound Kangfuxin Liquid liniment treated of the application, no patient abandons treating, and effect is good.
2) blister squama type and hyperkeratotic pattern tinea of feet and hands
Individually using A, B, C, (wherein, A (adds concentration of volume percent for salicylic acid tincture A by 1.6g salicylic acids
75% ethanol is settled to 100ml and is formulated), B is Kangfuxin Liquid, and C is the compound Kangfuxin Liquid liniment of the application) treatment water
Blister squama type and hyperkeratotic pattern tinea of feet and hands, per smearing 1-4 times beyond the highest heavens, carry out observation of curative effect in common 2-6 weeks.
Curative effect judging standard 1. is fully recovered：Skin lesion is disappeared completely；It is 2. effective：Skin lesion is substantially disappeared up to more than 60%；It is 3. effective：
Skin lesion regression 20%-40%；It is 4. invalid：Skin lesion, which is disappeared, is less than 20%, or skin lesion without change or continues to aggravate.
Total effective rate=(recovery from illness number of cases+effective number of cases)/this total cases * 100%.
Statistics is as follows：
Over the course for the treatment of, part severe patient can use compound Kangfuxin Liquid liniment to soak, and it is small first once to soak 1-2
When, soak 1 time every other day, it is 2-3 times common, after decortication, then immersion 20-30 minutes daily, continuous 2-4 days, it can greatly increase treatment
Effect.And salicylic acid tincture A is due to comparison stimulus, it is impossible in this way.As seen from the above table, using compound Kangfuxin Liquid liniment
Cure rate and obvious effective rate are higher.
3) tinea versicolor
Individually using A, B, C, (wherein, A (adds concentration of volume percent for salicylic acid tincture A by 1.6g salicylic acids
75% ethanol is settled to 100ml and is formulated), B is Kangfuxin Liquid, and C is the compound Kangfuxin Liquid liniment of the application) treatment flower
Spot tinea, per smearing 1-4 times beyond the highest heavens, carries out observation of curative effect in common 2-6 weeks by totally 30.
Curative effect judging standard 1. is fully recovered：Skin lesion is disappeared completely；It is 2. effective：Skin lesion is substantially disappeared up to more than 60%；It is 3. effective：
Skin lesion regression 20%-40%；It is 4. invalid：Skin lesion, which is disappeared, is less than 20%, or skin lesion without change or continues to aggravate.
Total effective rate=(recovery from illness number of cases+effective number of cases)/this total cases * 100%.
Statistics is as follows：
| N (example) | Fully recover (example) | Effective (example) | Effectively (example) | Invalid (example) | Efficient (%) | |
| A | 15 | 5 (33.3%) | 4 (26.7%) | 3 (20%) | 3 (20%) | 80 |
| B | 15 | 0 | 0 | 0 | 15 | 0 |
| C | 30 | 12 (40%) | 10 (33.3%) | 4 (13.3%) | 4 (13.3%) | 86.67 |
Salicylic acid tincture A and compound Kangfuxin Liquid the liniment effective percentage when treating tinea versicolor are not much different, but in therapeutic process
There is the patient feels discomfort of the part using salicylic acid tincture A, and do not felt like oneself using the patient of compound Kangfuxin Liquid liniment.
By above-mentioned 3 forms as it can be seen that compound Kangfuxin Liquid liniment is curative for effect in dermatophyte class disease is treated, especially
Treatment to jock itch, curative effect are preferable；The treatment of tinea of feet and hands, patient satisfaction are higher；Also there is certain therapeutic effect to tinea versicolor.And
It is individually invalid using Kangfuxin Liquid treatment dermatophyte class disease.
(3) papular urticaria
Clinical test is carried out to 80 papular urticaria patients using the compound Kangfuxin Liquid liniment of the application, as a result table
The itch of bright wherein 76 patients can effectively be alleviated, and being left 4 patient's itch also has certain alleviation, and total effective rate is up to 95%.
As it can be seen that compound Kangfuxin Liquid liniment has papular urticaria good antipruritic effect.
(4) hand Dry skin pruritus
The clinical observation that compound Kangfuxin Liquid liniment treats 150 hand Dry skin pruritus patients is used alone,
The result shows that efficient up to more than 90%, patient satisfaction is up to 85%.Wherein, the reason for satisfaction is not high enough is that some women is suffered from
Person must be often in contact with water, abluent or with rubber gloves etc., so that Relapse rate, is difficult to control, protracted course of disease.
(5) in addition, compound Kangfuxin Liquid liniment is also subacute to part and chronic eczema, atopic dermatitis, non-ulceration
Epifolliculitis etc. has a better effect.
The compound Kangfuxin Liquid liniment proposed according to the present invention and preparation method thereof optional factor is more, can be designed that more
Kind embodiment, therefore exemplary illustration of the specific embodiment only as specific implementation of the invention, without forming to this
The limitation of invention scope.In order to specifically describe the present invention, contributing to those skilled in the art to further understand the present invention, select
It is illustrative to select following embodiments.It should be pointed out that to those skilled in the art, this is not being departed from
On the premise of inventive concept, various modifications and improvements can be made.These belong to protection scope of the present invention.
Claims (3)
- A kind of 1. compound Kangfuxin Liquid liniment, it is characterised in that：Include the raw material of volumes below ratio：Salicylic acid tincture 49-51mlKangfuxin Liquid 73-77ml,Wherein salicylic acid tincture adds the ethanol of concentration of volume percent 75% to be settled to 100ml and is formulated by 4g salicylic acid tinctures.
- 2. compound Kangfuxin Liquid liniment according to claim 1, it is characterised in that：Include the raw material of volumes below ratio：Salicylic acid tincture 50mlKangfuxin Liquid 75ml.
- A kind of 3. preparation method of the compound Kangfuxin Liquid liniment described in claim 1 or 2, it is characterised in that：Including below according to The step of sequence carries out：1. taking salicylic acid 4g, the ethanol for adding concentration of volume percent 75% thereto is settled to 100ml and mixes, and bigcatkin willow is made Sour tincture；2. taking the desired amount of salicylic acid tincture, Kangfuxin Liquid is added thereto, is mixed, that is, the compound Kangfuxin Liquid is made and puts on the skin Agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810007411.1A CN107998151B (en) | 2018-01-04 | 2018-01-04 | Compound rehabilitation liquid liniment and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810007411.1A CN107998151B (en) | 2018-01-04 | 2018-01-04 | Compound rehabilitation liquid liniment and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107998151A true CN107998151A (en) | 2018-05-08 |
| CN107998151B CN107998151B (en) | 2022-04-19 |
Family
ID=62049607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810007411.1A Active CN107998151B (en) | 2018-01-04 | 2018-01-04 | Compound rehabilitation liquid liniment and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107998151B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004100152A4 (en) * | 2004-03-02 | 2004-04-01 | Robert Alan Armstrong | The Psoriasis Ointment |
| CN101703679A (en) * | 2009-11-10 | 2010-05-12 | 阚恭勇 | Medicament for treating onychomycosis |
| CN104435020A (en) * | 2013-09-22 | 2015-03-25 | 成都百草和济科技有限公司 | Composition for improving skin quality and application thereof |
| CN105640995A (en) * | 2016-03-01 | 2016-06-08 | 四川好医生攀西药业有限责任公司 | Pharmaceutical composition and applications thereof |
| CN106070202A (en) * | 2006-02-15 | 2016-11-09 | 博塔诺凯普有限公司 | The application of microencapsulated essential oils |
-
2018
- 2018-01-04 CN CN201810007411.1A patent/CN107998151B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004100152A4 (en) * | 2004-03-02 | 2004-04-01 | Robert Alan Armstrong | The Psoriasis Ointment |
| CN106070202A (en) * | 2006-02-15 | 2016-11-09 | 博塔诺凯普有限公司 | The application of microencapsulated essential oils |
| CN101703679A (en) * | 2009-11-10 | 2010-05-12 | 阚恭勇 | Medicament for treating onychomycosis |
| CN104435020A (en) * | 2013-09-22 | 2015-03-25 | 成都百草和济科技有限公司 | Composition for improving skin quality and application thereof |
| CN105640995A (en) * | 2016-03-01 | 2016-06-08 | 四川好医生攀西药业有限责任公司 | Pharmaceutical composition and applications thereof |
Non-Patent Citations (3)
| Title |
|---|
| 周涛等: ""手足癣的治疗"", 《中国中医药报》 * |
| 宋澄清等: "《临床合理用药指南》", 31 March 2008, 湖北科学技术出版社 * |
| 陈德兴: "《全科医生中成药手册》", 31 January 2015, 海科学技术出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107998151B (en) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104352587B (en) | A kind of ointment for treating rhinitis | |
| CN1736423A (en) | Method for preparing externally applied medicine for feet tinea | |
| CN103656025B (en) | A kind of medical liquor for treating injury | |
| CN104800700B (en) | It is a kind of to treat dermopathic herbal composite | |
| CN103977194A (en) | Application of drug for external use capable of effectively treating wound infection in preparing medicaments for treating diabetic foot | |
| CN107998151A (en) | Compound kangfuxin liquid liniment and preparation method thereof | |
| CN102698086B (en) | Chinese medicinal emulsion for treating bedsore accumulated toxin decay | |
| CN104352687A (en) | Drug for treating external hemorrhoids and preparation method thereof | |
| CN101983650A (en) | Medicament for treating dermatitis aestivale | |
| CN100488547C (en) | Pharmaceutical composition for treating tinea and complication thereof | |
| CN104306734B (en) | Treat diabetic gangrene externally applied ointment preparation and preparation method thereof | |
| CN116585404B (en) | External traditional Chinese medicine composition for treating adult simple skin pruritus and preparation method thereof | |
| CN108420980A (en) | It is a kind of treat skin injury, bacterium infection antibacterial ointment and preparation method thereof | |
| CN108186807A (en) | A kind of Chinese medicine composition for treating perianal | |
| CN108635362A (en) | A kind of pharmaceutical composition for treating diabetes | |
| CN107875213A (en) | A kind of Chinese medicine and its application method for treating anal intestine disease postoperative complications | |
| CN107029072A (en) | A kind of Hibisci Paste with antiinflammatory action | |
| CN107050049A (en) | A kind of external application bactericide for treating deep fungal dermatoses | |
| CN105832909A (en) | Traditional Chinese medicine preparation for treating necrotic ulcer of skin | |
| CN109718354A (en) | A kind of Chinese medicinal liniment for treating limb swelling after apoplexy | |
| CN1315496C (en) | Embedding catgut soaking liquor for treating psoriasis and its preparation method | |
| CN104208433A (en) | Traditional Chinese medicine preparation for treating tinea of feet and hands | |
| CN116211923A (en) | Traditional Chinese medicine medicated bath preparation for treating tinea, and preparation method and application thereof | |
| CN108619220A (en) | A kind of external medicine composition and preparation method thereof for treating hemorrhoid | |
| CN107802750A (en) | A kind of Chinese medicine composition for treating dermatophytosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |